Literature DB >> 20632969

Group I metabotropic glutamate receptor signalling and its implication in neurological disease.

Fabiola M Ribeiro1, Maryse Paquet, Sean P Cregan, Stephen S G Ferguson.   

Abstract

Stimulation of Group I metabotropic glutamate receptors (mGluR1 and mGluR5) leads to activation of a wide variety of signalling pathways. mGluRs couple to Gα(q/)₁₁ proteins, activating phospholipase Cβ1 resulting in both diacylglycerol and inositol-1,4,5-triphosphate formation followed by the activation of protein kinase C. In addition, mGluR activation can lead to modulation of a number of ion channels, such as different types of calcium and potassium channels. Group I mGluRs can also activate other downstream protein kinases, such as ERK1/2 and AKT, which are implicated in cellular growth, differentiation, and survival. Moreover, Group I mGluRs interact with a variety of different proteins that are important for the regulation of synaptic signalling, such as Homer and PDZ domain containing proteins, such as Tamalin. A role for mGluR1/5 in a number of disease states has also been proposed. As mGluR1/5 signal transduction is complex and involves multiple partners, a better understanding of alterations in mGluR signalling in brain disorders will be required in order to discern the molecular and cellular basis of these pathologies. This review will highlight recent findings concerning mGluR signaling alterations in brain pathologies, such as stroke, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy, and drug addiction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20632969     DOI: 10.2174/187152710793361612

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  65 in total

Review 1.  Metabotropic glutamate receptor subtype 5: molecular pharmacology, allosteric modulation and stimulus bias.

Authors:  K Sengmany; K J Gregory
Journal:  Br J Pharmacol       Date:  2015-11-11       Impact factor: 8.739

2.  Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery.

Authors:  Kathy Sengmany; Junaid Singh; Gregory D Stewart; P Jeffrey Conn; Arthur Christopoulos; Karen J Gregory
Journal:  Neuropharmacology       Date:  2016-07-05       Impact factor: 5.250

Review 3.  Amyloid beta: structure, biology and structure-based therapeutic development.

Authors:  Guo-Fang Chen; Ting-Hai Xu; Yan Yan; Yu-Ren Zhou; Yi Jiang; Karsten Melcher; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2017-07-17       Impact factor: 6.150

4.  The mGluR5 positive allosteric modulator VU0409551 improves synaptic plasticity and memory of a mouse model of Huntington's disease.

Authors:  Juliana G Doria; Jessica M de Souza; Flavia R Silva; Isabella G Olmo; Toniana G Carvalho; Juliana Alves-Silva; Talita H Ferreira-Vieira; Jessica T Santos; Claudymara Q S Xavier; Nathalia C Silva; Esther M A Maciel; Peter Jeffrey Conn; Fabiola M Ribeiro
Journal:  J Neurochem       Date:  2018-09-11       Impact factor: 5.372

Review 5.  The excitatory neurotransmitter glutamate stimulates DNA repair to increase neuronal resiliency.

Authors:  Jenq-Lin Yang; Peter Sykora; David M Wilson; Mark P Mattson; Vilhelm A Bohr
Journal:  Mech Ageing Dev       Date:  2011-06-25       Impact factor: 5.432

Review 6.  The role of glutamate and its receptors in multiple sclerosis.

Authors:  Ivana R Stojanovic; Milos Kostic; Srdjan Ljubisavljevic
Journal:  J Neural Transm (Vienna)       Date:  2014-03-15       Impact factor: 3.575

7.  Antagonism of metabotropic glutamate 1 receptors attenuates behavioral effects of cocaine and methamphetamine in squirrel monkeys.

Authors:  Cindy Achat-Mendes; Donna M Platt; Roger D Spealman
Journal:  J Pharmacol Exp Ther       Date:  2012-07-18       Impact factor: 4.030

8.  Identification of type 2 diabetes subgroups through topological analysis of patient similarity.

Authors:  Li Li; Wei-Yi Cheng; Benjamin S Glicksberg; Omri Gottesman; Ronald Tamler; Rong Chen; Erwin P Bottinger; Joel T Dudley
Journal:  Sci Transl Med       Date:  2015-10-28       Impact factor: 17.956

9.  Identification of Nitazoxanide as a Group I Metabotropic Glutamate Receptor Negative Modulator for the Treatment of Neuropathic Pain: An In Silico Drug Repositioning Study.

Authors:  Ni Ai; Richard D Wood; William J Welsh
Journal:  Pharm Res       Date:  2015-03-12       Impact factor: 4.200

10.  Kinetic analysis of the metabotropic glutamate subtype 5 tracer [(18)F]FPEB in bolus and bolus-plus-constant-infusion studies in humans.

Authors:  Jenna M Sullivan; Keunpoong Lim; David Labaree; Shu-Fei Lin; Timothy J McCarthy; John P Seibyl; Gilles Tamagnan; Yiyun Huang; Richard E Carson; Yu-Shin Ding; Evan D Morris
Journal:  J Cereb Blood Flow Metab       Date:  2012-12-19       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.